光化性角化病: ZYCLARA(R) Cream EU approved for actinic keratosis

 Zyclara获欧盟委员会批准用于治疗光化性角化病（AK） 发布时间：2012-8-29 来源：药品资讯网信息中心瑞典制药公司Meda周一宣布，Zyclara获欧盟委员会（EC）批准在欧盟各国上市销售。Zyclara，即3.75%咪喹莫特乳膏是用于治疗光化性角化病（AK）的专利药物。 Meda公司表示，光化性角化病为一种诊断不足、缺医少药且患病人群逐年增加的早期皮肤原位癌。Zyclara是目前第一种经临床证明的光化性角化病治疗方案，该药能够检出并消除光化性角化病所致大面积皮肤的亚临床及临床病变。 临床试验中，Zyclara不仅能够有效减缓光化性角化病所致的两种皮肤病变，且治愈后复发率很低。 Meda公司首席执行官Anders Lonner表示，"皮肤癌患者正逐年增加，而对光化性角化病的治疗方案的开发与改进就显得尤为重要。Zyclara的独特之处在于它是唯一可以治疗大面积皮肤病变的药物。

ZYCLARA® Cream is a prescription medication for use on the skin (topical) to treat actinic keratosis (AK) of the full face or balding scalp in adults with normal immune function. It is not known if ZYCLARA Cream is safe and effective for the topical treatment of AK in children less than 18 years of age. AKs are small, red, sometimes scaly, or rough patches that can be found on the full face or balding scalp, which are often exposed to the sun. ZYCLARA Cream has been shown to reduce AKs. Ask your doctor if ZYCLARA is right for you.